Last reviewed 2026-05-20 · How we verify

Afloxan (PROGLUMETACIN)

Phase 2 active Small molecule ✓ Verified May 2026 Quality 24/100

Afloxan (generic name: PROGLUMETACIN) is a proglumetacin drug. It is currently in Phase 2 development for Arthritis, Osteoarthritis, Rheumatoid arthritis.

Afloxan works by inhibiting the activity of enzymes called lipoxygenases, which play a role in the production of inflammatory mediators.

Afloxan is a small molecule with the synonyms PROGLUMETACIN, PROGLUMETACINA, and PROGLUMETACINE.

Likelihood of approval

16.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PROGLUMETACIN
Drug class	proglumetacin
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

Think of it like a fire alarm system in your body. When you have an injury or infection, your body sends out chemical signals to alert the immune system to come and fight the problem. Afloxan helps to turn off these signals, reducing the amount of inflammation and pain in the affected area.

Approved indications

Arthritis
Osteoarthritis
Rheumatoid arthritis

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Afloxan CI brief — competitive landscape report
Afloxan updates RSS · CI watch RSS

Frequently asked questions about Afloxan

What is Afloxan?

Afloxan (PROGLUMETACIN) is a proglumetacin drug, indicated for Arthritis, Osteoarthritis, Rheumatoid arthritis.

How does Afloxan work?

Afloxan works by inhibiting the activity of enzymes called lipoxygenases, which play a role in the production of inflammatory mediators.

What is Afloxan used for?

Afloxan is indicated for Arthritis, Osteoarthritis, Rheumatoid arthritis.

What is the generic name of Afloxan?

PROGLUMETACIN is the generic (nonproprietary) name of Afloxan.

What drug class is Afloxan in?

Afloxan belongs to the proglumetacin class. See all proglumetacin drugs at /class/proglumetacin.

What development phase is Afloxan in?

Afloxan is in Phase 2.

Drug class: All proglumetacin drugs
Therapeutic area: All drugs in Immunology
Indication: Drugs for Arthritis
Indication: Drugs for Osteoarthritis
Indication: Drugs for Rheumatoid arthritis

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing